Muscle Growth Research Peptides

25 research peptides demonstrate muscle growth properties. This collection covers their mechanisms, evidence base, and research applications.

Ipamorelin is recognized as one of the most selective growth hormone secretagogues (GHS) available. This synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) effectively stimulates the release of growth hormone (GH) from the pituitary gland while having minimal impact on cortisol, prolactin, or appetite. Research indicates that Ipamorelin binds selectively to the Growth Hormone Secretagogue Receptor (GHS-R1a) on somatotroph cells, which leads to an increase in cAMP levels and activation of protein kinase A, ultimately promoting GH secretion. Its unique structure allows it to target only the GH-releasing pocket of the ghrelin receptor, avoiding the activation of pathways that stimulate hunger or elevate cortisol levels seen with other peptides like GHRP-6. With a half-life of approximately 2 hours, studies suggest that multiple daily doses may be necessary to maintain its effects. Notably, Ipamorelin appears to maintain receptor sensitivity over extended use, potentially allowing for prolonged administration periods without diminished efficacy.

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that was initially developed to address HIV-associated lipodystrophy. It exists in two forms: one with a Drug Affinity Complex (DAC) that extends its half-life to 5.8-8.1 days, and a shorter-acting form known as Mod GRF 1-29, which has a half-life of about 30 minutes. Clinical trials, including those by Teichman et al. in 2006, have demonstrated that CJC-1295 can induce dose-dependent increases in GH and IGF-1 levels, with reported elevations of 2-10 fold for GH and 1.5-3 fold for IGF-1 in healthy adults. The mechanism involves binding to GHRH receptors on pituitary somatotrophs, leading to enhanced transcription of the GH gene and subsequent release of GH, which in turn elevates IGF-1 levels critical for muscle repair and growth. While the DAC version can lead to non-physiological GH levels and potential receptor desensitization, the Mod GRF variant mimics natural pulsatile GH release, thereby reducing risks associated with constant hormone elevation.

Sermorelin is a synthetic peptide consisting of 29 amino acids that mirrors the structure of the first segment of natural growth hormone-releasing hormone (GHRH). Its design aims to preserve the body's natural GH feedback mechanisms, primarily through somatostatin, making it a potentially safer alternative to exogenous human growth hormone (HGH). The pivotal 1997 trial published in the Journal of Clinical Endocrinology and Metabolism (JCEM) provided significant evidence regarding its efficacy, showing improvements in IGF-1 levels, body composition, and overall well-being over a 5-month period. Sermorelin operates by binding to GHRH receptors in the anterior pituitary, stimulating both the transcription of the HGH gene and the pulsatile release of endogenous GH. This endogenous release promotes protein synthesis and tissue repair while maintaining the negative feedback loop, thereby mitigating risks such as insulin resistance associated with exogenous HGH use. With a half-life of approximately 11-12 minutes, the biological effects initiated by Sermorelin may persist for weeks, suggesting a prolonged influence on metabolic processes.

GHRP-6, or Growth Hormone-Releasing Peptide 6, is a synthetic hexapeptide that acts as a potent growth hormone secretagogue by binding to the ghrelin receptor (GHS-R1a). This peptide is notable for its ability to stimulate pulsatile GH release while also promoting appetite, a characteristic attributed to its ghrelin-mimetic activity. Preclinical studies have demonstrated that GHRP-6 not only enhances GH levels but also exhibits cytoprotective properties through interactions with the CD36 receptor, which may confer benefits such as cardioprotection and neuroprotection. The mechanism of action involves the activation of GHS-R1a, leading to increased GH and IGF-1 levels while maintaining physiological feedback controls. This feedback mechanism is crucial, as it prevents excessive hormone levels by stimulating somatostatin release in response to elevated GH and IGF-1. With a half-life of approximately 2.5 hours, GHRP-6's multifaceted effects extend beyond mere endocrine activity, highlighting its potential in various therapeutic contexts.

GHRP-2, also known as pralmorelin, is a synthetic hexapeptide that functions as a growth hormone secretagogue with a more potent profile than GHRP-6, while exhibiting less appetite stimulation. Approved in Japan for diagnosing GH deficiency, GHRP-2 has been clinically utilized in pediatric populations with growth deficiencies, demonstrating sustained efficacy over extended treatment durations of 8-24 months. Research indicates that GHRP-2 binds to ghrelin receptors on somatotrophs, leading to robust GH release in a dose-dependent manner. In healthy adults, a single subcutaneous dose of 100 mcg can effectively stimulate GH secretion. Unlike continuous GH administration, GHRP-2 maintains physiological feedback mechanisms, allowing for once-daily dosing that balances efficacy and receptor recovery, thereby minimizing the risk of tachyphylaxis. Additionally, GHRP-2 has been shown to moderately stimulate cortisol and prolactin release, although to a lesser extent than GHRP-6. Its clinical utility as a diagnostic tool is underscored by the ability to distinguish GH deficiency from healthy controls based on GH response.

MK-677 (Ibutamoren) is recognized as a potent, orally-active growth hormone secretagogue that acts through the ghrelin receptor (GHS-R1a). Studies indicate that MK-677 can stimulate growth hormone release in a sustained manner, maintaining elevated levels of GH and IGF-1 for up to 24 hours post-administration. This characteristic differentiates it from injectable peptides such as GHRP-6, as MK-677 offers a convenient oral alternative. Its mechanism involves mimicking ghrelin, activating pathways that enhance the pulsatile release of growth hormone while preserving the hypothalamic-pituitary axis. Notably, MK-677 does not appear to influence cortisol levels at therapeutic doses, making it a subject of interest for research into muscle growth and metabolic health.

Hexarelin is a synthetic hexapeptide that serves as a potent growth hormone secretagogue, engaging the ghrelin receptor (GHS-R1a) to elicit significant GH release. Research indicates that Hexarelin may produce greater GH responses than GHRH alone, although its rapid receptor desensitization necessitates shorter administration cycles of 4-8 weeks. Importantly, Hexarelin exhibits cardioprotective properties that are independent of its GH-releasing effects, as evidenced by its ability to bind CD36 receptors on cardiac tissues. Its multifaceted mechanism includes stimulating pituitary somatotroph cells, enhancing GHRH release from the hypothalamus, and inhibiting somatostatin, thereby contributing to its robust GH pulse profile.

IGF-1 LR3 is a modified variant of insulin-like growth factor 1 (IGF-1), characterized by an extended N-terminal sequence and an amino acid substitution that enhances its potency and half-life. Research shows that IGF-1 LR3 has a significantly longer half-life of 20-30 hours compared to native IGF-1, allowing for sustained anabolic effects. This peptide engages IGF-1 receptors with high affinity, activating the PI3K/Akt/mTOR signaling pathway, which is crucial for promoting muscle protein synthesis and inhibiting catabolic processes. Furthermore, IGF-1 LR3 is known to stimulate satellite cell proliferation, contributing to muscle hyperplasia, and has been documented to enhance nutrient partitioning, making it a potent anabolic agent in preclinical models.

PEG-MGF (Pegylated Mechano Growth Factor) represents a synthetic version of MGF, designed to extend its half-life and enhance its systemic availability. Research highlights that native MGF is produced in response to mechanical overload, playing a critical role in muscle repair by activating satellite cells. However, its short half-life limits its therapeutic potential. PEGylation mitigates this issue, allowing for prolonged circulation and activity. Mechanistically, PEG-MGF stimulates satellite cell proliferation through an IGF-1R-independent pathway, facilitating muscle regeneration without triggering premature differentiation. This distinct action underscores its potential utility in muscle recovery and performance enhancement, although it remains prohibited by WADA and lacks approval for human therapeutic use.

Follistatin 344 is a growth factor that functions primarily by inhibiting myostatin, a negative regulator of muscle growth. Preclinical studies have demonstrated that follistatin can promote muscle hypertrophy by blocking myostatin's signaling pathways. Gene therapy approaches utilizing follistatin have been explored in clinical trials for conditions such as Becker muscular dystrophy, although the recombinant protein version available from research suppliers has limited human data. The mechanism involves high-affinity binding to myostatin and activins, preventing their interaction with receptors that mediate muscle growth inhibition. Despite its promise, follistatin's short half-life of approximately 2-4 hours due to rapid hepatic clearance presents challenges for sustained therapeutic application.

Alexamorelin is a synthetic growth hormone-releasing peptide (GHRP) that shares structural similarities with GHRP-6. Although it has been investigated for its potential as a GH secretagogue, the body of research surrounding Alexamorelin remains sparse, with limited preclinical studies and no advancement to significant clinical trials. Its proposed mechanism involves acting as a ghrelin receptor (GHS-R1a) agonist, stimulating GH release from the anterior pituitary through both hypothalamic and direct pituitary pathways. However, the lack of comprehensive pharmacological characterization in the literature limits the understanding of its efficacy and potential applications in muscle growth research.

Tabimorelin (NN703) is a synthetic growth hormone secretagogue that has undergone Phase I and II clinical trials, demonstrating its ability to stimulate growth hormone (GH) release in both healthy individuals and those with GH deficiencies. Despite its promising pharmacological profile, development of Tabimorelin was halted, potentially due to an unfavorable efficacy-to-side-effect ratio for long-term use. Nonetheless, it remains one of the more thoroughly characterized oral GH secretagogues in the literature.

Mechanistically, Tabimorelin functions as an agonist at the ghrelin receptor (GHS-R1a), leading to the stimulation of GH release from the anterior pituitary gland. Its oral bioavailability is a notable distinction from injectable growth hormone-releasing peptides (GHRPs). Clinical studies indicate that single oral doses can elicit dose-dependent GH release, with peak levels observed within 30 to 60 minutes post-administration. Additionally, Tabimorelin has been shown to modestly increase cortisol, prolactin, and adrenocorticotropic hormone (ACTH), consistent with the pharmacological effects expected from GHS-R1a agonists.

Mechano Growth Factor (MGF) is a splice variant of insulin-like growth factor 1 (IGF-1), specifically derived from the E-domain of the IGF-1Ec isoform. This peptide is produced in response to mechanical stress in muscle tissue and plays a critical role in muscle repair and the activation of satellite cells, which are essential for muscle regeneration. While MGF has been studied for its potential in enhancing muscle growth, it is primarily a research compound, with no clinical trials conducted to date, and it is banned by the World Anti-Doping Agency (WADA).

The mechanism of MGF involves its expression through alternative splicing of the IGF-1 gene, activated by mechanical overload or tissue injury. The E-domain peptide uniquely stimulates satellite cells, contributing to the repair and growth of muscle fibers. MGF enhances protein synthesis through pathways that are partially independent of the IGF-1 receptor. However, the synthetic form of MGF has a very short half-life in vivo, estimated at only a few minutes due to rapid degradation by proteases, which significantly limits its systemic bioactivity unless modified, such as in the PEGylated variant (PEG-MGF).

IGF-1 DES (Des(1-3)IGF-1) is a truncated variant of insulin-like growth factor 1 that lacks the first three N-terminal amino acids (Gly-Pro-Glu). This structural modification enhances its potency at the IGF-1 receptor (IGF-1R) by reducing its binding affinity to insulin-like growth factor binding proteins (IGFBPs), resulting in a tenfold increase in activity compared to native IGF-1 in certain tissue contexts. IGF-1 DES is naturally occurring in the brain as a product of post-translational processing, but it is exclusively used in research settings and is banned by WADA.

The mechanism of action for IGF-1 DES involves its binding to IGF-1R with similar affinity to native IGF-1, but with significantly reduced interaction with IGFBPs, which typically sequester the majority of circulating IGF-1. This leads to a higher bioactive fraction, facilitating enhanced activation of critical signaling pathways such as PI3K/Akt and MAPK/ERK, which are vital for promoting cellular proliferation, survival, and protein synthesis. While the truncated form is found in human brain tissue and bovine colostrum, the lack of clinical trials limits the understanding of its full therapeutic potential and safety profile.

Human growth hormone (hGH, somatotropin) is a 191-amino acid protein synthesized by the anterior pituitary gland and is one of the most extensively studied hormones in the field of medicine. Its pivotal role in growth, metabolism, and overall physiological function has led to its FDA approval for specific indications, including growth hormone deficiency and certain conditions associated with short stature.

The mechanism of action of growth hormone involves binding to the growth hormone receptor (GHR), a type I cytokine receptor, which activates the JAK2-STAT5 signaling pathway. This activation stimulates hepatic production of insulin-like growth factor 1 (IGF-1), mediating many of the anabolic effects attributed to GH. Additionally, GH exerts direct metabolic effects, stimulating lipolysis in adipose tissue, promoting protein synthesis in muscle, and influencing glucose metabolism with anti-insulin (diabetogenic) effects. GH is secreted in a pulsatile manner, predominantly during slow-wave sleep, with an endogenous half-life of approximately 20-30 minutes. However, recombinant human growth hormone (rhGH) administered via subcutaneous injection has an effective duration of action lasting 12-16 hours, acting on nearly all tissues in the body.